Business
The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.
FEATURED STORIES
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.
He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
SomaLogic and Illumina have come together to propel innovation in Proteomics. This partnership represents the rapidly growing high throughput sector of the proteomics market
Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.
Formerly Esker Therapeutics, a San Francisco-based biotech company, now named Alumis, closed on a $200 million Series B financing round to help advance its precision immunology medicines.
The acquisition is expected to bolster Odyssey’s drug development capabilities in immunology and oncology.